- Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
- Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder
- Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights
- Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors
- Alto Neuroscience to Participate in Upcoming Investor Conferences
- Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference
- Alto Neuroscience Announces Pricing of Upsized Initial Public Offering
More ▼
Key statistics
On Friday, Alto Neuroscience Inc (ANRO:NYQ) closed at 14.18, 10.96% above the 52 week low of 12.78 set on Apr 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 13.94 |
---|---|
High | 14.18 |
Low | 13.94 |
Bid | 13.30 |
Offer | 15.91 |
Previous close | 14.13 |
Average volume | 88.58k |
---|---|
Shares outstanding | 26.88m |
Free float | 23.36m |
P/E (TTM) | -- |
Market cap | 381.21m USD |
EPS (TTM) | -1.42 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 21:10 BST.
More ▼